Does concomitant methotrexate with adalimumab influence treatment outcomes in patients with psoriatic arthritis? Data from a large observational study

Journal of Rheumatology

Volumn 43, Issue 3, 2016, Pages 632-639

  Behrens, Frank ^a   Koehm, Michaela ^a,b   Arndt, Uta ^c   Wittig, Bianca M ^d   Greger, Gerd ^d   Thaçi, Diamant ^e   Scharbatke, Eva ^f   Tony, Hans Peter ^f   Burkhardt, Harald ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME   (Germany)

^c Rheumapraxis Hofheim   (Germany)

^d ABBVIE INC   (United States)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^f UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Adalimumab; Anti tumor necrosis factor therapy; Concomitant therapy; Methotrexate; Psoriatic arthritis

Indexed keywords

ADALIMUMAB; METHOTREXATE; ANTIRHEUMATIC AGENT;

ADULT; ARTICLE; BODY SURFACE; CONTROLLED STUDY; DAS28; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GERMANY; HUMAN; INFECTION; INFESTATION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MUSCULOSKELETAL DISEASE ASSESSMENT; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PSORIASIS; PSORIASIS TARGET LESION SCORE; PSORIATIC ARTHRITIS; RETROSPECTIVE STUDY; SKIN DISEASE ASSESSMENT; SPINE DISEASE; SWOLLEN JOINT COUNT; TENDER JOINT COUNT; TREATMENT OUTCOME; ARTHRITIS, PSORIATIC; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DISEASE COURSE; MIDDLE AGED; MULTICENTER STUDY;

ADALIMUMAB; ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84959918934     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.141596     Document Type: Article

References (19)

1. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate therapy. Arthritis Rheum 2006;54:26-37.
2. van der Heijde D, Klareskog L, Rodriguez-Valverde V, Codreanu C, Bolosiu H, Melo-Gomes J, et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: Two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 2006;54:1063-74.
3. Hyrich KL, Symmons DPM, Watson KD, Silman AJ, British Society for Rheumatology Biologics Register. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006;54:1786-94.
4. Behrens F, Cañeta JD, Olivieri I, van Kuijk AW, McHugh N, Combe B. Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: A systematic review of the literature. Rheumatology 2015;54:915-26.
5. Kingsley GH, Kowalczyk A, Taylor H, Ibrahim F, Packham JC, McHugh NJ, et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology 2012;51:1368-77.
6. Kristensen LE, Gülfe A, Saxne T, Geborek P. Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register. Ann Rheum Dis 2008;67:364-9.
7. Heiberg MS, Koldingsnes W, Mikkelsen K, Rødevand E, Kaufmann C, Mowinckel P, et al. The comparative one-year performance of anti-tumour necrosis factor α drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum 2008;59:234-40.
8. Fagerli KM, Lie E, van der Heijde D, Heiberg MS, Lexberg AS, Rødevand E, et al. The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study. Ann Rheum Dis 2013;73:132-7.
9. Gladman DD, Mease PJ, Ritchlin CT, Choy EH, Sharp JT, Ory PA, et al. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial. Arthritis Rheum 2007;56:476-88.
10. Gossec L, Smolen JS, Gaujoux-Viala C, Ash Z, Marzo-Ortega H, van der Heijde D, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012;71:4-12.
11. Lubrano E, Spadaro A. Axial psoriatic arthritis: an intriguing clinical entity or a subset of an intriguing disease. Clin Rheumatol 2012;31:1027-32.
12. Ujfalussy I, Koo E. Measurement of disease activity in psoriatic arthritis. Extended report. Z Rheumatol 2003;62:60-5.
13. Fransen J, Antoni C, Mease PJ, Uter W, Kavanaugh A, Kalden JR, et al. Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors. Ann Rheum Dis 2006;35:1373-8.
14. Woolson RF. Multiple linear regression. In: Woolson RF, ed. Statistical methods for the analysis of biomedical data. New York: John Wiley & Sons Inc.; 1987:295-300.
15. Listing J, Strangfeld A, Rau R, Kekow J, Gromnica-Ihle E, Klopsch T, et al. Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low - results from RABBIT, the German biologics register. Arthritis Res Ther 2006;8:R66.
16. Vogelzang EH, Kneepkens EL, Nurmohamed MT, van Kuijk AW, Rispens T, Wolbink G, et al. Anti-adalimumab antibodies and adalimumab concentrations in psoriatic arthritis; an association with disease activity at 28 and 52 weeks of follow-up. Ann Rheum Dis 2014;73:2178-82.
17. Vogelzang EH, Pouw MF, Nurmohamed M, Kneepkens EL, Rispens T, Wolbink GJ, et al. Adalimumab trough concentrations in patients with rheumatoid arthritis and psoriatic arthritis treated with concomitant disease-modifying antirheumatic drugs. Ann Rheum Dis 2015;74:474-5.
18. Willkens RF, Williams HJ, Ward JR, Egger MJ, Reading JC, Clements PJ, et al. Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum 1984;27:376-81.
19. Helliwell PS, Taylor WJ, CASPAR Study Group. Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs - comparison of drugs and adverse reactions. J Rheumatol 2008;35:472-6.